ALNY - Citi says concerns over FDA approval of Alnylam drug are overdone
2023-09-15 14:04:22 ET
More on Alnylam Pharmaceuticals
- Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals
- Historical earnings data for Alnylam Pharmaceuticals
- Financial information for Alnylam Pharmaceuticals
- Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
- Alnylam: Unlimited Promise Or Unlimited Losses?
- Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Alnylam Pharmaceuticals, Inc. ( NASDAQ: ALNY ) Q2 2023 Earnings Call Transcript
- Alnylam stock falls after FDA panel questions drug's effectiveness
- Alnylam wins FDA panel backing additional Onpattro indications
- Alnylam stock trading halted as FDA AdCom meets on amyloidosis drug
- Alnylam amyloidosis drug led to “small” benefits in Phase 3 trial: FDA
For further details see:
Citi says concerns over FDA approval of Alnylam drug are "overdone"